Live online and onsite in Würzburg!
The therapeutic landscape in DLBCL is constantly changing and new drugs are expanding our therapeutic options. For a long time, R-CHOP was considered as first-line standard of care. With the Polarix trial there is a new therapeutic option available. CAR-T cells continue to establish themselves in the 2nd and 3rd line of therapy and bispecific antibodies are implemented in the relapse setting and pushing into the first line.
However, the many new options also pose a challenge to physicians to make the right treatment decisions. We will therefore focus on which therapeutic options suit which patient. With our DLBCL preceptorship we are happy to offer a platform where we all can exchange ideas with colleagues and learn from each other. Whether on site in Würzburg or live online: we are looking forward to a highly informative and excitingevent and a lively exchange with you!
Universitätsklinikum Würzburg A.ö.R.
Incyte Biosciences International Sàrl
Rue Dr Yersin 12